FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Summary: FibroBiologics, Inc. announced the successful release and shipment of the first clinical batch of CYWC628, its fibroblast-based spheroid therapeutic candidate, for the upcoming Phase 1/2 trial in patients with diabetic foot ulcers (DFU). This milestone positions the company to begin patient enrollment and dosing. CYWC628 aims to harness the regenerative power of fibroblasts to improve healing in chronic DFUs.
Key Highlights:
- First GMP batch of CYWC628 released and shipped for clinical use
- Phase 1/2 trial in DFU patients now imminent
- Novel fibroblast spheroid approach targeting regenerative wound healing
- Part of broader platform with 270+ patents in regenerative medicine
Keywords: CYWC628, FibroBiologics DFU, fibroblast spheroids